Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > The Take-Over

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Mar 26, 2024 3:29pm

49 Views

Post# 35953769

RE:RE:RE:RE:RE:RE:RE:RE:The Take-Over

It's right in the bloody NR....

The proposed transaction also has to be approved by an affirmative vote of at least a simple majority of the votes cast by shareholders of RepliCel present in person or represented by proxy and entitled to vote at the meeting, excluding the votes cast by Mr. Schutte for common shares held either directly or indirectly in accordance with Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions, as further discussed below.

<< Previous

Bullboard Posts

Next >>

Aston Bay unearths thick new copper zones in Nunavut